MedTrace Logo

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-08-29

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of intravitreal injection of aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS).

Conditions

  • Choroidal Neovascularization
  • Presumed Ocular Histoplasmosis

Interventions

DRUG

EYLEA (Aflibercept) intravitreal injection

Intravitreal Injection once every 8 weeks with 3 initial monthly doses

Sponsors & Collaborators

  • Retina Research Institute, LLC

    lead OTHER

Principal Investigators

  • Kevin J Blinder, MD · The Retina Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-04-30
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578720 on ClinicalTrials.gov